Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.


Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
14 May 2024
Historique:
received: 23 01 2024
revised: 25 03 2024
accepted: 09 05 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 16 5 2024
Statut: aheadofprint

Résumé

Natural Killer (NK) cells have high intrinsic cytotoxic capacity, and clinical trials have demonstrated their safety and efficacy for adoptive cancer therapy. Expression of chimeric antigen receptors (CARs) enhances NK cell target-specificity, with these cells applicable as 'off-the-shelf' products generated from allogeneic donors. Here, we present for the first time an innovative approach for CAR NK cell engineering employing a non-viral Sleeping Beauty (SB) transposon/transposase-based system and minimized DNA vectors termed minicircles. SB-modified peripheral blood-derived primary NK cells displayed high and stable CAR expression and more frequent vector integration into 'genomic safe harbors' than lentiviral vectors. Importantly, SB-generated CAR NK cells demonstrated enhanced cytotoxicity compared to non-transfected NK cells. A strong antileukemic potential was confirmed using established acute lymphocytic leukemia (ALL) cells and patient-derived primary B-ALL samples as targets in vitro and in vivo in a xenograft leukemia mouse model. Our data suggest that the SB-transposon system is an efficient, safe and cost-effective approach to non-viral engineering of highly functional CAR NK cells, which may be suitable for cancer immunotherapy of leukemia as well as many other malignancies.

Identifiants

pubmed: 38751112
pii: S1525-0016(24)00320-4
doi: 10.1016/j.ymthe.2024.05.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Tobias Bexte (T)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; University Cancer Center (UCT) Frankfurt; Mildred Scheel Career Center (MSNZ), Hospital of the Goethe University Frankfurt, Germany.

Lacramioara Botezatu (L)

Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.

Csaba Miskey (C)

Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.

Fenja Gierschek (F)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.

Alina Moter (A)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.

Philipp Wendel (P)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt am Main, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Lisa Marie Reindl (LM)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.

Julia Campe (J)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.

Jose Francisco Villena-Ossa (JF)

Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Freiburg, Germany.

Veronika Gebel (V)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; University Cancer Center (UCT) Frankfurt; Mildred Scheel Career Center (MSNZ), Hospital of the Goethe University Frankfurt, Germany.

Katja Stein (K)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; University Cancer Center (UCT) Frankfurt.

Toni Cathomen (T)

Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Freiburg, Germany; Faculty of Medical, University of Freiburg, Freiburg, Germany.

Anjali Cremer (A)

Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; University Cancer Center (UCT) Frankfurt; Mildred Scheel Career Center (MSNZ), Hospital of the Goethe University Frankfurt, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.

Winfried S Wels (WS)

Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt am Main, Germany; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Freiburg, Germany.

Michael Hudecek (M)

Faculty of Medical, University of Freiburg, Freiburg, Germany.

Zoltán Ivics (Z)

Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Evelyn Ullrich (E)

Goethe University, Department of Pediatrics, Experimental Immunology and Cell Therapy, Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany; University Cancer Center (UCT) Frankfurt; Mildred Scheel Career Center (MSNZ), Hospital of the Goethe University Frankfurt, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt am Main, Germany. Electronic address: evelyn@ullrichlab.de.

Classifications MeSH